Literature DB >> 1768557

Population pharmacokinetics: theory and practice.

L Aarons1.   

Abstract

Mesh：

Year:  1991        PMID： 1768557      PMCID： PMC1368544     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  17 in total

1.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

2.  Controversy. IV: Population pharmacokinetics, NONMEM and the pharmacokinetic screen; academic, industrial and regulatory perspectives.

Authors:  W A Colburn
Journal:  J Clin Pharmacol       Date:  1989-01       Impact factor: 3.126

3.  The population pharmacokinetics of theophylline in neonates and young infants.

Authors:  E S Moore; R G Faix; R C Banagale; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

4.  Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: a sensitivity analysis.

Authors:  S Vozeh; C Steiner
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

5.  Premarketing observational studies of population pharmacokinetics of new drugs.

Authors:  L B Sheiner; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

Review 6.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

7.  Population pharmacokinetics of mitoxantrone performed by a NONMEM method.

Authors:  M C Launay; A Iliadis; B Richard
Journal:  J Pharm Sci       Date:  1989-10       Impact factor: 3.534

Review 8.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

9.  Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials.

Authors:  N M Graves; T M Ludden; G B Holmes; R H Fuerst; I E Leppik
Journal:  Pharmacotherapy       Date:  1989       Impact factor: 4.705

10.  Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models.

Authors:  M S Driscoll; T M Ludden; D T Casto; L C Littlefield
Journal:  J Pharmacokinet Biopharm       Date:  1989-04
View more
  47 in total

1.  Software for population pharmacokinetics and pharmacodynamics.

Authors:  L Aarons
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

Review 2.  Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Authors:  Cindy J Bednasz; Charles S Venuto; Qing Ma; Gene D Morse
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

3.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

4.  Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed.

Authors:  L Aarons
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 5.  Clinical pharmacology = disease progression + drug action.

Authors:  Nick Holford
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

6.  Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

Authors:  Yan Feng; Bruce G Pollock; Kim Coley; Stephen Marder; Del Miller; Margaret Kirshner; Manickam Aravagiri; Lon Schneider; Robert R Bies
Journal:  Br J Clin Pharmacol       Date:  2008-07-31       Impact factor: 4.335

7.  How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Eur J Clin Pharmacol       Date:  2008-05-16       Impact factor: 2.953

Review 8.  Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposure.

Authors:  Jong Hwan Sung; Balaji Srinivasan; Mandy Brigitte Esch; William T McLamb; Catia Bernabini; Michael L Shuler; James J Hickman
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-20

Review 9.  Population pharmacokinetics. A regulatory perspective.

Authors:  H Sun; E O Fadiran; C D Jones; L Lesko; S M Huang; K Higgins; C Hu; S Machado; S Maldonado; R Williams; M Hossain; E I Ette
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 10.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.